1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

10 Nov 2023
Admin
News Article

AstraZeneca inks billion dollar deal with Chinese startup Eccogene

China-based startup Eccogene has entered into an exclusive license agreement with UK-based pharmaceutical firm AstraZeneca to develop and commercialise Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities.

Preliminary results from the Phase I trial have shown a differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight reduction across the dose levels tested compared to placebo.

GLP-1RAs are an important treatment option for people living with metabolic diseases such as diabetes and obesity. They have been shown to be effective at decreasing haemoglobin A1c (HbA1c), promoting weight loss and reducing the risk of cardiovascular events by mimicking the hormone GLP-1.

Under the terms of the agreement, Eccogene will receive an initial upfront payment of $185 million. In addition, Eccogene will be eligible to receive up to an additional $1.825 billion in future clinical, regulatory, and commercial milestones. Eccogene is further eligible to receive tiered royalties on net product sales.

In exchange, AstraZeneca will receive exclusive rights to develop and commercialise Eccogene's ECC5004 small molecule GLP-1RA for any indication in all territories except China. Eccogene and AstraZeneca will partner for co-development and co-commercialisation of ECC5004 in China.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!